TIMP1 and metabolic dysfunction-associated steatotic liver disease: Recent clinical study has shown that GS-0976 reduced serum TIMP-1 in patients with NAFLD [27, 36], suggesting translation of the anti-fibrosis effect from liver-targeted ACC1/2 dual inhibition in NASH patients.